RXRX is trading 6.2% up at $3.35 as market participants weigh a potential short-squeeze narrative in the AI-driven drug discovery space against heavy short interest.
- Traders are reacting to a speculative biotech backdrop and recent Form 4 and 8-K filings detailing insider selling and governance updates.
- Despite the upward price action, no single company-specific catalyst has been disclosed in the latest session, suggesting the move is driven by technical positioning and sector sentiment.